Get the Stockscreener App
1.64
20.48%
-0.46
Celularity Inc stock is traded at $1.64, with a volume of 12.24M.
It is down -20.48% in the last 24 hours and up +119.71% over the past month.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
See More
Previous Close:
$2.10
Open:
$2.145
24h Volume:
12.24M
Relative Volume:
116.90
Market Cap:
$47.18M
Revenue:
$26.55M
Net Income/Loss:
$-91.72M
P/E Ratio:
-0.4576
EPS:
-3.584
Net Cash Flow:
$-13.25M
1W Performance:
+108.74%
1M Performance:
+119.71%
6M Performance:
+35.77%
1Y Performance:
-56.62%
1-Day Range:
$1.61
$2.20
1-Week Range:
$0.749
$2.55
52-Week Range:
$0.5601
$4.00
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.63 | 22.20M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
541.81 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.92 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,030.35 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.40 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
206.80 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity (CELU) Levels: Finishes 1.41% Down at $0.77 in Latest Trading; Range Check: the Near-Term Reference Band Stretches From $0.73 to $0.81 under the Current SnapshotPrice Momentum Stocks - vinanet.vn
Celularity (CELU) Earnings Snapshot: The EPS Result Is Above Expectation on the Day; Share Move: Shares Move 5.89% Higher in the Current UpdateEPS Surprise History - vinanet.vn
Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition - TipRanks
NEXGEL Q2 2026: Revenue $3.69M, Net Loss $2.87M as Company Transitions Post-Acquisition - TradingView
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (CELU) delays June 2026 10-Q filing amid liquidity and staffing strain - Stock Titan
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy - Stock Titan
CELU Q4 2025 Earnings: Narrower Loss Beats Estimates by 44.44% as Shares Rise 0.72Profit Margin Analysis - vinanet.vn
Celularity (CELU) Slips 2% as Stock Holds Between $0.66 Support and $0.72 ResistancePut Support - vinanet.vn
Celularity Announces Sudden Exit of Chief Commercial Officer - The Globe and Mail
Celularity Inc. Files Form 8-K as Emerging Growth Company on NASDAQ CELU Shares - Minichart
Celularity removes chief commercial officer Rick Gonzalez effective immediately - Investing.com
Form 8K Celularity Inc For: 7 August By Investing.com - Investing.com Nigeria
Celularity terminates Rick Gonzalez as Chief Commercial Officer - TradingView
Celularity (NASDAQ: CELU) terminates employment of chief commercial officer - Stock Titan
Celularity Inc Announces Termination of Rick Gonzalez from Chief Commercial Officer, Effective August 5, 2026 - marketscreener.com
Celularity Inc (CELU) Stock News Today - TradingKey
Celularity removes chief commercial officer Rick Gonzalez effective immediately By Investing.com - Investing.com Canada
Celularity Inc (CELU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nasdaq issues bid-price deficiency notice to Celularity (NASDAQ: CELU) - Stock Titan
CELU|Celularity Inc|Price:0.780|Chg%:+0.030 - TradingKey
Celularity Inc (CELU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celularity Inc (CELU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Celularity Inc (CELU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celularity Inc (CELU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Celularity Inc (CELU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Celularity Inc (CELU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Celularity Inc (CELU) Institutional Confidence - TradingKey
Celularity Inc (CELU) Income Statement - TradingKey
TradingKey - TradingKey
Celularity Inc. (CELU) Q4 2025 Earnings: Narrower-Than-Expected Loss as Operational Discipline ImprovesSegment Revenue Breakdown - dars.gov.et
Philip & Daniele Barach Family Trust Net Worth (2026) - GuruFocus
Celularity Inc. (CELU) Q4 2025 Earnings: EPS Surprise Beats Estimates as Losses Narrow SharplyBalance Sheet Strength - dars.gov.et
Celularity Inc. (CELU) warrants delisted and deregistered from Nasdaq exchange - Stock Titan
Celularity Inc. (CELU) Edges Higher as Stock Tests Resistance Near $0.83Synthetic Short - dars.gov.et
CELU Q4 2025 Earnings: EPS Beat Signals Cost Discipline Despite Revenue AbsenceOne-Time Gain Impact - vinanet.vn
Celularity Q4 2025 Earnings: EPS Surpasses Estimates by 44.4% Amid Strategic ProgressMargin Expansion Trends - vinanet.vn
Press Release: Celularity Appoints Rick Gonzalez as Chief Commercial Officer - Moomoo
Number of shareholders of Celularity Inc. – NASDAQ:CELUW - TradingView
Price to sales forward of Celularity Inc. – NASDAQ:CELUW - TradingView
CELU Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Stock HigherRevenue Growth Outlook - dars.gov.et
Celularity Inc. Warrant 2021-16.07.26 on Celularity -A- Financial Disclosures & SEC Filings - TradingView
Celularity Inc. Announces Resignation of Vincent LeVien as Director, Effective June 26, 2026 - marketscreener.com
Celularity Inc. Enters into a Loan Agreement with the Philip & Daniele Barach Family Trust - marketscreener.com
Celularity Company Profile & Introduction - Moomoo
Celularity Inc. Secures $1 Million Loan from Philip & Daniele Barach Family Trust – Form 8-K Filing Details and Key Agreement Terms 141519 - Minichart
CELULARITYSECURES $1 MLN LOAN FROM PHILIP & DANIELE BARACH FAMILY TRUSTSEC FILING - Moomoo
Celularity director Vincent LeVien resigns from board - TradingView
Insider trust lends $1M to Celularity (NASDAQ: CELU) on short term - Stock Titan
CelularityEnters Loan Agreement With Phili - Moomoo
Celularity Inc (NASDAQ: CELU) Share Price, CELU Stock News, CELU Share Price & Updates - Kalkine
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celularity Inc Stock (CELU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haines John R | Senior Exec Vice President |
Apr 13 '26 |
Option Exercise |
0.00 |
1,641 |
0 |
30,762 |
| Hariri Robert J | Chief Executive Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
3,281 |
0 |
2,854,735 |
2.14%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):